Borreliosis
Serum
Performed by: Bioscientia International
Understanding the Borreliosis Biomarker Category: Insights into Lyme Disease and Related Tick-Borne Infections
The biomarker category "Borreliosis" encompasses a range of biomarkers used in diagnosing Lyme disease and other infections caused by Borrelia species. Lyme disease, the most common form of borreliosis, is caused by Borrelia burgdorferi, transmitted through tick bites. Due to the complexity of Borrelia infections, clinicians use multiple biomarkers—including Borrelia WB IgM, Borrelia WB IgG, and P100—to identify the presence and stage of the disease. Together, these biomarkers provide a layered view of the immune response to Borrelia infection, helping determine whether an infection is recent, persistent, or past.
Key Borreliosis Biomarkers: Borrelia WB IgM, Borrelia WB IgG, and P100
In the borreliosis category, Borrelia WB IgM, Borrelia WB IgG, and P100 are essential markers. Each reflects different stages and characteristics of the immune response to Borrelia infection:
- Borrelia WB IgM: This marker is produced early in infection, typically within 1-2 weeks post-exposure. A positive IgM indicates a recent or active infection.
- Borrelia WB IgG: IgG antibodies develop later, generally after 4-6 weeks, and indicate an established or past immune response.
- P100: This antigen is more often associated with chronic or late-stage Lyme disease, appearing in cases where the immune system has been engaged with Borrelia for an extended period.
These three markers together create a comprehensive profile, allowing clinicians to assess the infection stage and duration more accurately.
Interpretive Matrix for Borreliosis Biomarkers
The following matrix provides an overview of possible interpretations based on combinations of results for Borrelia WB IgM, Borrelia WB IgG, and P100. Each result combination reflects different infection stages or diagnostic implications.
| Borrelia WB IgM | Borrelia WB IgG | P100 | Interpretation |
|---|---|---|---|
| Positive | Negative | Negative | Early-Stage Infection: Suggests recent exposure with early IgM response. IgG and P100 may not have developed yet. |
| Positive | Positive | Negative | Intermediate Infection: Infection is progressing, with early IgG response accompanying IgM, but P100 has not appeared. |
| Positive | Positive | Positive | Advanced or Chronic Infection: Prolonged infection suggested by ongoing IgM and IgG responses and later-stage P100 reactivity. |
| Negative | Positive | Negative | Past or Resolved Infection: IgG alone indicates prior exposure, with no current IgM or chronic markers present. |
| Negative | Positive | Positive | Chronic or Persistent Infection: IgG and P100 together indicate ongoing immune response and possible chronic infection. |
| Negative | Negative | Positive | Atypical or Persistent Immune Response: P100 reactivity without IgM or IgG is unusual; further investigation is recommended to rule out other causes. |
| Negative | Negative | Negative | No Evidence of Infection: Absence of all markers suggests no current or past infection or that testing occurred too early for antibody detection. |
Clinical Significance of Each Biomarker Combination
This matrix serves as a diagnostic guide, offering insights into each result pattern:
-
Early Infection: Positive IgM with negative IgG and P100 results typically indicates an early-stage infection. This combination suggests the immune system has recently encountered Borrelia burgdorferi and has begun producing IgM antibodies. Early treatment is essential to prevent progression.
-
Intermediate Stage: When both IgM and IgG are positive but P100 is still negative, the infection may be progressing from early to intermediate stages. This indicates the body’s immune response is developing further, as IgG begins to appear.
-
Chronic Infection: Positive IgG and P100 with negative IgM usually indicate a chronic or persistent infection, where IgG and P100 reactivity reflect a prolonged immune response. If symptoms are consistent with late-stage Lyme disease, further clinical management may be necessary.
-
Atypical Response: In cases where only P100 is positive and IgM and IgG are negative, the interpretation is more complex. P100 positivity alone might suggest an atypical immune response to Borrelia burgdorferi, prompting further investigation through additional testing, such as PCR or testing for other tick-borne infections.
Challenges and Limitations of Borreliosis Biomarkers
Although these biomarkers are valuable, interpreting them can be challenging due to variability in immune responses. For example, not all patients develop detectable antibodies at the same rate, and Borrelia’s ability to evade the immune system can result in delayed or absent IgM and IgG responses. False positives may also occur, particularly with IgM, due to cross-reactivity with other infections or autoimmune conditions. Consequently, these markers are most effective when used alongside clinical findings, history of exposure, and other tests as needed.
Additional Testing and Follow-up
If the biomarker results are inconclusive, additional testing may be beneficial. PCR (Polymerase Chain Reaction) testing, which detects Borrelia DNA directly, can confirm an active infection when standard antibody markers are negative. Retesting after a few weeks may also capture changes in antibody levels as the infection progresses. Testing for other co-infections, such as Babesia or Ehrlichia, may also be necessary, as co-infections can mimic Lyme disease symptoms and influence test results.
Conclusion
The Borreliosis biomarker category, consisting of Borrelia WB IgM, Borrelia WB IgG, and P100, provides a comprehensive approach to diagnosing Lyme disease and assessing its stage. By examining these markers together, healthcare providers gain a clearer understanding of the immune response to Borrelia burgdorferi, helping to differentiate early, chronic, and past infections. While these biomarkers are powerful diagnostic tools, they are most effective when used in conjunction with clinical evaluation, patient history, and, if needed, additional testing. This integrated approach enhances diagnostic accuracy and informs treatment strategies, supporting better patient outcomes in managing Lyme disease and related infections.
Show more
Biomarkers included in this panel:
Borrelia WB IgG
The Borrelia Western Blot IgG (Immunoglobulin G) is a vital component in the diagnostic process for Lyme disease, an infection caused by the bacterium Borrelia burgdorferi. IgG antibodies are part of the body’s adaptive immune response and typi
Learn moreBorrelia-WB-IgM
The Borrelia Western Blot (WB) IgM test is a significant tool in the diagnosis of Lyme disease, an infection caused by the Borrelia burgdorferi bacteria, transmitted primarily through tick bites. The IgM test specifically detects early immune respons
Learn morep100
When it comes to diagnosing Lyme disease, a condition caused by the Borrelia burgdorferi bacteria, healthcare providers often rely on a combination of clinical evaluation, patient symptoms, and specific laboratory tests. One of the components sometim
Learn more